AA
TVTX icon

ALPS Advisors’s Travere Therapeutics TVTX Stock Holding History

ALPS Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.23M Buy
75,096
+1,833
+3% +$54.8K 0.01% 382
2025
Q4 		$2.8M Buy
73,263
+26,020
+55% +$846K 0.02% 338
2025
Q3 		$1.13M Sell
47,243
-705
-1% -$13.3K 0.01% 489
2025
Q2 		$710K Buy
+47,948
New +$795K ﹤0.01% 581
2024
Q2 		– Sell
-53,672
Closed -$414K – 1003
2024
Q1 		$414K Buy
53,672
+6,617
+14% +$55.8K ﹤0.01% 618
2023
Q4 		$423K Sell
47,055
-8,319
-15% -$60.6K ﹤0.01% 637
2023
Q3 		$495K Buy
55,374
+531
+1% +$7.49K ﹤0.01% 599
2023
Q2 		$842K Buy
54,843
+6,731
+14% +$122K 0.01% 525
2023
Q1 		$1.08M Buy
48,112
+4,612
+11% +$98K 0.01% 455
2022
Q4 		$915K Buy
43,500
+8,587
+25% +$182K 0.01% 501
2022
Q3 		$860K Sell
34,913
-2,766
-7% -$71.5K 0.01% 496
2022
Q2 		$913K Sell
37,679
-27,576
-42% -$694K 0.01% 496
2022
Q1 		$1.68M Sell
65,255
-5,599
-8% -$149K 0.02% 258
2021
Q4 		$2.2M Sell
70,854
-3,557
-5% -$100K 0.02% 281
2021
Q3 		$1.8M Sell
74,411
-5,214
-7% -$95.8K 0.02% 331
2021
Q2 		$1.16M Sell
79,625
-29,350
-27% -$579K 0.01% 388
2021
Q1 		$2.72M Buy
108,975
+16,963
+18% +$469K 0.03% 228
2020
Q4 		$2.51M Buy
+92,012
New +$2.15M 0.03% 243

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ALPS Advisors's TVTX Position: Q1 2026 in Review

ALPS Advisors increased its Travere Therapeutics (TVTX) stake by 2.5% in Q1 2026, buying an estimated $54.8K and bringing the position to 75,096 shares worth $2.23M. The position accounts for 0.01% of the portfolio, ranked #382.

ALPS Advisors first reported a position in TVTX in Q4 2020 and has held it in 18 quarters since. The position peaked at $2.8M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • ALPS Advisors held 75,096 shares of Travere Therapeutics worth $2.23M as of Q1 2026.
  • ALPS Advisors bought 1,833 Travere Therapeutics shares in Q1 2026, an estimated $54.8K.
  • Travere Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #382 holding.
  • ALPS Advisors first reported a position in Travere Therapeutics in Q4 2020 and has held it in 18 quarters since.
  • ALPS Advisors's Travere Therapeutics position peaked at $2.8M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.